Literature DB >> 3781624

Plasmid RP1-mediated susceptibility of Acinetobacter calcoaceticus to rat polymorphonuclear leukocyte granule contents.

M J Loeffelholz, M C Modrzakowski.   

Abstract

The resistance plasmid RP1 was transferred by conjugation to a plasmidless strain of Acinetobacter calcoaceticus. Acquisition and expression of RP1 by A. calcoaceticus HO1-N was associated with an increase in sensitivity to the antimicrobial activity of extracted contents from rat polymorphonuclear leukocyte granules. Plasmid RP1-associated antibiotic resistance and sensitivity to granule contents were cured by exposure to acridine orange. Assays with granule extract fractions separated by fast protein liquid chromatography showed myeloperoxidase, protease, and lysozyme fractions to possess little or no antimicrobial activity against the A. calcoaceticus strains. A protein fraction designated peak D, containing two low-molecular-weight cationic peptides (M. J. Loeffelholz and M. C. Modrzakowski, Anal. Biochem., in press), did possess antimicrobial activity against both HO1-N and Ho1-N(RP1) strains, with the HO1-N(RP1) strain being significantly more sensitive.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3781624      PMCID: PMC260226          DOI: 10.1128/iai.54.3.705-709.1986

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  28 in total

1.  Purification and characterization of a potent bactericidal and membrane active protein from the granules of human polymorphonuclear leukocytes.

Authors:  J Weiss; P Elsbach; I Olsson; H Odeberg
Journal:  J Biol Chem       Date:  1978-04-25       Impact factor: 5.157

2.  Host range and properties of the Pseudomonas aeruginosa R factor R1822.

Authors:  R H Olsen; P Shipley
Journal:  J Bacteriol       Date:  1973-02       Impact factor: 3.490

3.  Bactericidal activity of fractionated granule contents from human polymorphonuclear leukocytes.

Authors:  M C Modrzakowski; M H Cooney; L E Martin; J K Spitznagel
Journal:  Infect Immun       Date:  1979-03       Impact factor: 3.441

4.  Mechanisms for the microbicidal activity of cationic proteins of human granulocytes.

Authors:  H Odeberg; I Olsson
Journal:  Infect Immun       Date:  1976-12       Impact factor: 3.441

5.  Bactericidal activity of granule contents from rat polymorphonuclear leukocytes.

Authors:  R L Hodinka; M C Modrzakowski
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

6.  Purification and antibacterial activity of antimicrobial peptides of rabbit granulocytes.

Authors:  M E Selsted; D Szklarek; R I Lehrer
Journal:  Infect Immun       Date:  1984-07       Impact factor: 3.441

7.  Bactericidal activity of fractionated granule contents from human polymorphonuclear leukocytes: antagonism of granule cationic proteins by lipopolysaccharide.

Authors:  M C Modrzakowski; J K Spitznagel
Journal:  Infect Immun       Date:  1979-08       Impact factor: 3.441

8.  Involvement of a plasmid in the invasive ability of Shigella flexneri.

Authors:  P J Sansonetti; D J Kopecko; S B Formal
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

9.  Endemic nosocomial Acinetobacter calcoaceticus bacteremia. Clinical significance, treatment, and prognosis.

Authors:  R A Smego
Journal:  Arch Intern Med       Date:  1985-12

10.  Arthritis in rats after systemic injection of streptococcal cells or cell walls.

Authors:  W J Cromartie; J G Craddock; J H Schwab; S K Anderle; C H Yang
Journal:  J Exp Med       Date:  1977-12-01       Impact factor: 14.307

View more
  2 in total

1.  Antimicrobial mechanisms against Acinetobacter calcoaceticus of rat polymorphonuclear leukocyte granule extract.

Authors:  M J Loeffelholz; M C Modrzakowski
Journal:  Infect Immun       Date:  1988-03       Impact factor: 3.441

2.  Outer membrane permeability of Acinetobacter calcoaceticus mediates susceptibility to rat polymorphonuclear leukocyte granule contents.

Authors:  M J Loeffelholz; M C Modrzakowski
Journal:  Infect Immun       Date:  1987-09       Impact factor: 3.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.